TY - JOUR
T1 - Sézary syndrome, recent biomarkers and new drugs
AU - Cristofoletti, Cristina
AU - Narducci, Maria Grazia
AU - Russo, Giandomenico
PY - 2019/2
Y1 - 2019/2
N2 - Sézary syndrome (SS) is a primary cutaneous T-cell lymphoma (CTCL) characterized by erythroderma, lymphadenopathy and leukemic involvement of the peripheral blood. The high relapse rates and a poor prognosis complicate its clinical course and treatment. The phenotypic characterization and genomic/transcriptomic approaches revealed high heterogeneity of Sezary cells, identifying a wide spectrum of biomarkers implicated in the development of this lymphoma. In this context, we discuss the major malignancy-related biomarkers reported in the literature for the diagnosis, prognosis and staging of SS. The hope for a single reliable diagnostic marker appears increasingly unrealistic, but the discovery of multiple potential biomarkers, with pathogenetic implications, paves the road to promising personalized therapies in SS.
AB - Sézary syndrome (SS) is a primary cutaneous T-cell lymphoma (CTCL) characterized by erythroderma, lymphadenopathy and leukemic involvement of the peripheral blood. The high relapse rates and a poor prognosis complicate its clinical course and treatment. The phenotypic characterization and genomic/transcriptomic approaches revealed high heterogeneity of Sezary cells, identifying a wide spectrum of biomarkers implicated in the development of this lymphoma. In this context, we discuss the major malignancy-related biomarkers reported in the literature for the diagnosis, prognosis and staging of SS. The hope for a single reliable diagnostic marker appears increasingly unrealistic, but the discovery of multiple potential biomarkers, with pathogenetic implications, paves the road to promising personalized therapies in SS.
KW - Biomarkers
KW - Clinical trials
KW - Cutaneous T-cell lymphoma (CTCL)
KW - Sézary syndrome (SS)
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=85062435201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062435201&partnerID=8YFLogxK
U2 - 10.21037/cco.2018.11.02
DO - 10.21037/cco.2018.11.02
M3 - Review article
C2 - 30525758
AN - SCOPUS:85062435201
VL - 8
JO - Chinese Clinical Oncology
JF - Chinese Clinical Oncology
SN - 2304-3865
IS - 1
M1 - 2
ER -